| Biomarkers in NHL |
|
https://doi.org/10.18632/oncotarget.252
Sami N. Malek
|
| 102-103 |
Chaperones and the maturation of steroid hormone receptor complexes
Chaperones and the maturation of steroid hormone receptor complexes |
|
https://doi.org/10.18632/oncotarget.238
Yizhi Jane Tao,
and Wenjie Zheng
|
| 104-106 |
Novel strategies of protecting non-cancer cells during chemotherapy: Are they ready for clinical testing?
Novel strategies of protecting non-cancer cells during chemotherapy: Are they ready for clinical testing? |
|
https://doi.org/10.18632/oncotarget.249
Zbigniew Darzynkiewicz
|
| 107-108 |
Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity |
|
https://doi.org/10.18632/oncotarget.247
Linda S. Steelman,
Alberto M. Martelli,
Ferdinando Nicoletti,
and James A. McCubrey
|
| 109-112 |
The Challenge for Gene Therapy: Innate Immune Response to Adenoviruses
The Challenge for Gene Therapy: Innate Immune Response to Adenoviruses |
|
https://doi.org/10.18632/oncotarget.231
Bart Thaci,
Ilya V. Ulasov,
Derek V. Wainwright,
and Maciej S. Lesniak
|
| 113-121 |
Recent Advances in Anti-Angiogenic Therapy of Cancer
Recent Advances in Anti-Angiogenic Therapy of Cancer |
|
https://doi.org/10.18632/oncotarget.234
Rajeev S. Samant,
and Lalita A. Shevde
|
| 122-134 |
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health |
|
https://doi.org/10.18632/oncotarget.240
William H. Chappell,
Linda S. Steelman,
Jacquelyn M. Long,
Ruth C. Kempf,
Stephen L. Abrams,
Richard A. Franklin,
Jörg Bäsecke,
Franca Stivala,
Marco Donia,
Paolo Fagone,
Graziella Malaponte,
Maria C. Mazzarino,
Ferdinando Nicoletti,
Massimo Libra,
Danijela Maksimovic-Ivanic,
Sanja Mijatovic,
Giuseppe Montalto,
Melchiorre Cervello,
Piotr Laidler,
Michele Milella,
Agostino Tafuri,
Antonio Bonati,
Camilla Evangelisti,
Lucio Cocco,
Alberto M. Martelli,
and James A. McCubrey
|
| 135-164 |
Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer |
|
https://doi.org/10.18632/oncotarget.245
Rodrigo Dienstmann,
Pablo Martinez,
and Enriqueta Felip
|
| 165-177 |
IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients
IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients |
|
https://doi.org/10.18632/oncotarget.235
Jian He,
Jian Wu,
Yuchen Jiao,
Nina Wagner-Johnston,
Richard F. Ambinder,
Luis A. Diaz,
Kenneth W. Kinzler,
Bert Vogelstein,
and Nickolas Papadopoulos
|
| 178-185 |
Inhibition of SREBP1 sensitizes cells to death ligands
Inhibition of SREBP1 sensitizes cells to death ligands |
|
https://doi.org/10.18632/oncotarget.239
Yanina Eberhard,
Marcela Gronda,
Rose Hurren,
Alessandro Datti,
Neil MacLean,
Troy Ketela,
Jason Moffat,
Jeffrey L. Wrana,
and Aaron D. Schimmer
|
| 186-196 |
APC +/- alters colonic fibroblast proteome in FAP
APC +/- alters colonic fibroblast proteome in FAP |
|
https://doi.org/10.18632/oncotarget.241
Bhavinkumar B. Patel,
Xin-Ming Li,
Maketa P. Dixon,
Elena L. Blagoi,
Emmanuelle Nicolas,
Steven H, Seeholzer,
David Cheng,
Yin A He,
Renata A Coudry,
Sharon D. Howard,
Dawn M. Riddle,
Harry S. Cooper,
Bruce M. Boman,
Peggy Conrad,
James A. Crowell,
Alfonso Bellacosa,
Alfred Knudson,
Anthony T. Yeung,
and Levy Kopelovich
|
| 197-208 |
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib |
|
https://doi.org/10.18632/oncotarget.246
Nickolay Neznanov,
Andrei P. Komarov,
Lubov Neznanova,
Patricia Stanhope-Baker,
and Andrei V. Gudkov
|
| 209-221 |
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture |
|
https://doi.org/10.18632/oncotarget.248
Pasha Apontes,
Olga V. Leontieva,
Zoya N. Demidenko,
Fengzhi Li,
and Mikhail V. Blagosklonny
|
| 222-233 |
The RP-Mdm2-p53 Pathway and Tumorigenesis
The RP-Mdm2-p53 Pathway and Tumorigenesis |
|
https://doi.org/10.18632/oncotarget.228
Paula L. Miliani de Marval,
and Yanping Zhang
|
| 234-238 |
Mcl-1 Ubiquitination and Destruction
Mcl-1 Ubiquitination and Destruction |
|
https://doi.org/10.18632/oncotarget.242
Hiroyuki Inuzuka,
Hidefumi Fukushima,
Shavali Shaik,
Pengda Liu,
Alan W. Lau,
and Wenyi Wei
|
| 239-244 |
Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders |
|
https://doi.org/10.18632/oncotarget.233
Mayumi Naramura,
Scott Nadeau,
Bhopal Mohapatra,
Gulzar Ahmad,
Chandrani Mukhopadhay,
Martin Sattler,
Srikumar M. Raja,
Amarnath Natarajan,
Vimla Band,
and Hamid Band
|
| 245-250 |
MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk |
|
https://doi.org/10.18632/oncotarget.243
Stian Knappskog,
and Per E. Lønning
|
| 251-258 |
A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity
A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity |
|
https://doi.org/10.18632/oncotarget.244
Benjamin Ory,
and Leif W. Ellisen
|
| 259-264 |
miRNA signature of schwannomas: Possible role(s) of “tumor suppressor” miRNAs in benign tumors
miRNA signature of schwannomas: Possible role(s) of “tumor suppressor” miRNAs in benign tumors |
|
https://doi.org/10.18632/oncotarget.251
Erdogan Pekcan Erkan,
Xandra O. Breakefield,
and Okay Saydam
|
| 265-270 |
